SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-062617
Filing Date
2021-05-07
Accepted
2021-05-06 20:25:20
Documents
14
Period of Report
2021-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2115510d1_8k.htm   iXBRL 8-K 28508
2 EXHIBIT 99.1 tm2115510d1_ex99-1.htm EX-99.1 50041
6 GRAPHIC image_001.jpg GRAPHIC 12703
  Complete submission text file 0001104659-21-062617.txt   277582

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA elox-20210506.xsd EX-101.SCH 3196
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE elox-20210506_lab.xml EX-101.LAB 34592
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elox-20210506_pre.xml EX-101.PRE 22717
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2115510d1_8k_htm.xml XML 3493
Mailing Address 950 WINTER STREET WALTHAM MA 02451
Business Address 950 WINTER STREET WALTHAM MA 02451 (858) 909-0749
Eloxx Pharmaceuticals, Inc. (Filer) CIK: 0001035354 (see all company filings)

IRS No.: 841368850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31326 | Film No.: 21899826
SIC: 8731 Services-Commercial Physical & Biological Research